Njoku Kelechi, Barr Chloe E, Crosbie Emma J
Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Stoller Biomarker Discovery Centre, University of Manchester, Manchester, United Kingdom.
Front Oncol. 2022 Apr 22;12:890908. doi: 10.3389/fonc.2022.890908. eCollection 2022.
Endometrial cancer is the most common gynaecological malignancy in high income countries and its incidence is rising. Whilst most women with endometrial cancer are diagnosed with highly curable disease and have good outcomes, a significant minority present with adverse clinico-pathological characteristics that herald a poor prognosis. Prognostic biomarkers that reliably select those at greatest risk of disease recurrence and death can guide management strategies to ensure that patients receive appropriate evidence-based and personalised care. The Cancer Genome Atlas substantially advanced our understanding of the molecular diversity of endometrial cancer and informed the development of simplified, pragmatic and cost-effective classifiers with prognostic implications and potential for clinical translation. Several blood-based biomarkers including proteins, metabolites, circulating tumour cells, circulating tumour DNA and inflammatory parameters have also shown promise for endometrial cancer risk assessment. This review provides an update on the established and emerging prognostic biomarkers in endometrial cancer.
子宫内膜癌是高收入国家最常见的妇科恶性肿瘤，其发病率正在上升。虽然大多数子宫内膜癌女性被诊断为具有高度可治愈性的疾病且预后良好，但仍有相当少数患者表现出预示预后不良的不良临床病理特征。能够可靠地筛选出疾病复发和死亡风险最高人群的预后生物标志物，可以指导管理策略，以确保患者获得适当的循证和个性化护理。癌症基因组图谱极大地增进了我们对子宫内膜癌分子多样性的理解，并为开发具有预后意义且有可能进行临床转化的简化、实用且经济高效的分类器提供了依据。包括蛋白质、代谢物、循环肿瘤细胞、循环肿瘤DNA和炎症参数在内的几种基于血液的生物标志物，在子宫内膜癌风险评估方面也显示出了前景。本综述提供了子宫内膜癌中已确立和新出现的预后生物标志物的最新信息。
